Insilico Medicine

Insilico Medicine uses generative AI and reinforcement learning to design novel drug molecules through its Chemistry42 platform, compressing what normally takes years into days. It made history advancing the first AI-designed drug candidate into Phase II trials for idiopathic pulmonary fibrosis, and went on to IPO on the Hong Kong Stock Exchange in 2024 — one of the first AI-native biotechs to go public.